3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Marijuana Abuse
2
Breast Neoplasms
2
Anxiety Disorders
2
Sturge-Weber Syndrome
1
Solid Tumor
1
Prostatic Neoplasms
1
Parasomnias
1
Pain
1
Nausea
1
Glioblastoma
1
Colonic Neoplasms
1
Cognitive Dysfunction
1
Chemotherapy-Induced Peripheral Neuropathy
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Cancer Pain
1
Breast Carcinoma In Situ
1
Arthralgia
1
Interventions
Morphine
6
Analgesia
6
nabiximols
3
Pregabalin
3
Oxycodone
3
Fentanyl
3
ziconotide
2
Surveys and Questionnaires
2
Saline Solution
2
Radiofrequency Ablation
2
Methadone
2
Lidocaine
2
Ketamine
2
Ibandronic Acid
2
Gemcitabine
2
Duloxetine Hydrochloride
2
Docetaxel
2
Botulinum Toxins, Type A
2
trimebutine 3-thiocarbamoylbenzenesulfonate
1
tanezumab
1
tandutinib
1
siltuximab
1
resiniferatoxin
1
incobotulinumtoxinA
1
imisopasem manganese
1
fulranumab
1
erenumab
1
cyclobenzaprine
1
caffeine, sodium benzoate drug combination
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pain
×
Cannabidiol
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled